14102 studies
Sodium-glucose cotransporter-2 (SGLT2) inhibitors are widely used to manage type 2 diabetes mellitus (T2DM) because of their glucose-lowering and cardioprotective effects. However, euglycemic diabetic ketoacidosis (euDKA) is an uncommon but serious a…
INTRODUCTION: Pharmacotherapy of depression represents a significant challenge in the management of depression in primary care. Although effective treatments have been available, many patients are still not adequately managed. Clinical pharmacists re…
Alopecia has recently been reported as a potential emerging adverse effect associated with glucagon-like peptide-1 receptor agonists (GLP-1RAs), which are widely prescribed for weight loss. While gastrointestinal symptoms remain the most frequently d…
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP1RAs) lead to substantial weight loss and pain reduction in persons with knee osteoarthritis and obesity. OBJECTIVE: To evaluate the cost-effectiveness of 2 GLP1RAs, semaglutide and tirzepatid…
BACKGROUND: Frailty is common in heart failure with preserved ejection fraction (HFpEF). In the STEP-HFpEF (Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity) program, semaglutide improved heart…
SUMMARY: Bariatric surgery and glucagon-like peptide-1 receptor agonist medications (GLP-1RAs) are common and effective methods for treating obesity. Since bariatric surgery is associated with an increased risk of malnutrition, there are extensive po…
The introduction of semaglutide, a glucagon-like-1 receptor agonist (GLP-1ra) as a weight-loss medication, has attracted considerable public and medical attention, reporting weight reductions of up to 15 %. However, its rapid adoption highlights the…
PURPOSE: This study used artificial intelligence (AI) and natural language processing (NLP) to analyze patient reviews of semaglutide, with the goal of better understanding its real-world effectiveness and safety for weight management. METHODS: A ret…
Tumor cells have substantially increased lipid biogenesis, which is primarily regulated by the activation of sterol regulatory element-binding protein (SREBP). However, whether SREBP regulation can be targeted for cancer treatment remains unclear. He…
IMPORTANCE: Obesity is a chronic condition with negative consequences for patients, the health care system, and society. The most effective treatment of class II and III obesity is metabolic bariatric surgery (MBS), which is usually considered a last…
Polycystic ovary syndrome (PCOS) is a common endocrine-metabolic disorder in reproductive-aged women, often associated with obesity and dyslipidemia. Semaglutide, a GLP-1 receptor agonist (GLP-1 RA), improves glycemic control and weight, but its effe…
Over the last three years, a combination of wildly growing demand and near-constant shortages have provided both compounding pharmacies and outsourcing facilities with strong financial incentives to move aggressively into the production and sale of s…
Discourse around the usage of weight-loss drugs (semaglutide, GLP-1 agonists, Ozempic, Wegovy) center around how people are precluded from access, a phenomenon understood as stratified biomedicalization. However, this research project finds people re…
BACKGROUND: Once-weekly subcutaneous semaglutide 2·4 mg is approved for weight management in people with obesity and related complications; however, some individuals do not reach their therapeutic goals with this dose. We aimed to test the efficacy a…
BACKGROUND: Semaglutide 2·4 mg is approved for weight management in adults with obesity or overweight in the presence of at least one obesity-related complication; however, many people with obesity and type 2 diabetes do not reach their bodyweight re…
Cardiovascular disease remains the leading cause of mortality worldwide, with obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH) serving as major upstream drivers. Current therapies largely address downstream risk f…
OBJECTIVE: This study aimed to evaluate the weight loss efficacy of semaglutide initiated 6 months after laparoscopic sleeve gastrectomy (LSG). METHODS: This retrospective study included patients undergoing primary LSG. Patients receiving semaglutide…